213 related articles for article (PubMed ID: 33970296)
1. Prognostic association of medication trajectories with 3-year mortality in heart failure and preserved ejection fraction: findings from the EPICAL2 cohort study.
Bitar S; Thilly N; Agrinier N
Eur J Clin Pharmacol; 2021 Oct; 77(10):1569-1581. PubMed ID: 33970296
[TBL] [Abstract][Full Text] [Related]
2. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Thomas J; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012721. PubMed ID: 29952095
[TBL] [Abstract][Full Text] [Related]
3. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
[TBL] [Abstract][Full Text] [Related]
4. Effect of Prescribing Patterns of Renin-Angiotensin System Blockers and Beta-Blockers on Prognosis of Heart Failure.
Kim HJ; Jo SH; Lee MH; Seo WW; Choi JO; Ryu KH
Adv Ther; 2020 Sep; 37(9):3839-3849. PubMed ID: 32676928
[TBL] [Abstract][Full Text] [Related]
5. Adherence to ESC guideline-recommended medications over a 36-month follow-up period after hospitalization for heart failure: Results from the EPICAL2 cohort study.
Bitar S; Agrinier N; Alla F; Rossignol P; Mebazaa A; Thilly N
Pharmacoepidemiol Drug Saf; 2019 Nov; 28(11):1489-1500. PubMed ID: 31339629
[TBL] [Abstract][Full Text] [Related]
6. Heart failure medication after a first hospital admission and risk of heart failure readmission, focus on beta-blockers and renin-angiotensin-aldosterone system medication: A retrospective cohort study in linked databases.
Kruik-Kollöffel WJ; van der Palen J; Doggen CJM; van Maaren MC; Kruik HJ; Heintjes EM; Movig KLL; Linssen GCM
PLoS One; 2020; 15(12):e0244231. PubMed ID: 33351823
[TBL] [Abstract][Full Text] [Related]
7. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
Albert NM; Tyson RJ; Hill CL; DeVore AD; Spertus JA; Duffy C; Butler J; Patterson JH; Hernandez AF; Williams FB; Thomas L; Fonarow GC
Am Heart J; 2021 May; 235():82-96. PubMed ID: 33497697
[TBL] [Abstract][Full Text] [Related]
8. Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: An analysis from the HELP-HF registry.
Tomasoni D; Pagnesi M; Colombo G; Chiarito M; Stolfo D; Baldetti L; Lombardi CM; Adamo M; Maggi G; Inciardi RM; Loiacono F; Maccallini M; Villaschi A; Gasparini G; Montella M; Contessi S; Cocianni D; Perotto M; Barone G; Merlo M; Cappelletti AM; Rosano G; Sinagra G; Pini D; Savarese G; Metra M
Eur J Heart Fail; 2024 Feb; 26(2):327-337. PubMed ID: 37933210
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Traditional Heart Failure Therapies in Patients With Cardiac Amyloidosis and Heart Failure.
Yan CL; Gallo RA; Vasquez Martinez M; Rivera Rodriguez B; Trujillo L; Thakkar Rivera N; Hoffman JE
Am J Cardiol; 2023 Oct; 204():360-365. PubMed ID: 37573615
[TBL] [Abstract][Full Text] [Related]
10. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction.
Lund LH; Benson L; Dahlström U; Edner M
JAMA; 2012 Nov; 308(20):2108-17. PubMed ID: 23188027
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of guideline-consistent heart failure drug prescriptions at hospital discharge on 1-year mortality: Results from the EPICAL2 cohort study.
Busson A; Thilly N; Laborde-Castérot H; Alla F; Messikh Z; Clerc-Urmes I; Mebazaa A; Soudant M; Agrinier N
Eur J Intern Med; 2018 May; 51():53-60. PubMed ID: 29305071
[TBL] [Abstract][Full Text] [Related]
12. Effects of angiotensin receptor blocker at discharge in patients with heart failure with reduced ejection fraction: Korean Acute Heart Failure (KorAHF) registry.
Choi KH; Lee GY; Choi JO; Jeon ES; Lee HY; Cho HJ; Lee SE; Kim MS; Kim JJ; Hwang KK; Chae SC; Baek SH; Kang SM; Choi DJ; Yoo BS; Kim KH; Park HY; Cho MC; Oh BH
Int J Cardiol; 2018 Apr; 257():168-176. PubMed ID: 29506690
[TBL] [Abstract][Full Text] [Related]
13. Gap between guidelines and clinical practice in heart failure with reduced ejection fraction: Results from TSOC-HFrEF registry.
Chang HY; Wang CC; Wei J; Chang CY; Chuang YC; Huang CL; Chong E; Lin JL; Mar GY; Chan KC; Kuo JY; Wang JH; Chen ZC; Tseng WK; Cherng WJ; Yin WH
J Chin Med Assoc; 2017 Dec; 80(12):750-757. PubMed ID: 29033112
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis.
Tseng AS; Kunze KL; Lee JZ; Amin M; Neville MR; Almader-Douglas D; Killu AM; Madhavan M; Cha YM; Asirvatham SJ; Friedman PA; Gersh BJ; Mulpuru SK
Circ Arrhythm Electrophysiol; 2019 Jun; 12(6):e006951. PubMed ID: 31159582
[TBL] [Abstract][Full Text] [Related]
15. Renin-Angiotensin System Inhibition and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries with Heart Failure.
Sanam K; Bhatia V; Bajaj NS; Gaba S; Morgan CJ; Fonarow GC; Butler J; Deedwania P; Prabhu SD; Wu WC; White M; Love TE; Aronow WS; Fletcher RD; Allman RM; Ahmed A
Am J Med; 2016 Oct; 129(10):1067-73. PubMed ID: 27262781
[TBL] [Abstract][Full Text] [Related]
16. Impact of clinical characteristics and management on the prognosis of unselected heart failure patients.
Eschalier R; Chenaf C; Mulliez A; Yalioua A; Clerfond G; Authier N; Vorilhon C; Citron B; Pereira B; Jean F; Souteyrand G; Motreff P; Eschalier A; Lusson JR
Cardiovasc Drugs Ther; 2015 Feb; 29(1):89-98. PubMed ID: 25700624
[TBL] [Abstract][Full Text] [Related]
17. Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF.
Beusekamp JC; Tromp J; van der Wal HH; Anker SD; Cleland JG; Dickstein K; Filippatos G; van der Harst P; Hillege HL; Lang CC; Metra M; Ng LL; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zwinderman AH; Rossignol P; Zannad F; Voors AA; van der Meer P
Eur J Heart Fail; 2018 May; 20(5):923-930. PubMed ID: 29327797
[TBL] [Abstract][Full Text] [Related]
18. Impact of renin-angiotensin-aldosterone system inhibition on morbidity and mortality during long-term continuous-flow left ventricular assist device support: An IMACS report.
Brinkley DM; Wang L; Yu C; Grandin EW; Kiernan MS
J Heart Lung Transplant; 2021 Dec; 40(12):1605-1613. PubMed ID: 34663529
[TBL] [Abstract][Full Text] [Related]
19. Effect of Heart Failure Pharmacotherapies in Patients with Heart Failure with Mildly Reduced Ejection Fraction.
Schupp T; Bertsch T; Reinhardt M; Abel N; Schmitt A; Lau F; Abumayyaleh M; Akin M; Weiß C; Weidner K; Behnes M; Akin I
Eur J Prev Cardiol; 2024 Mar; ():. PubMed ID: 38513366
[TBL] [Abstract][Full Text] [Related]
20. Effect of Optimizing Guideline-Directed Medical Therapy Before Discharge on Mortality and Heart Failure Readmission in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction.
Yamaguchi T; Kitai T; Miyamoto T; Kagiyama N; Okumura T; Kida K; Oishi S; Akiyama E; Suzuki S; Yamamoto M; Yamaguchi J; Iwai T; Hijikata S; Masuda R; Miyazaki R; Hara N; Nagata Y; Nozato T; Matsue Y
Am J Cardiol; 2018 Apr; 121(8):969-974. PubMed ID: 29477488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]